Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Fellow Finance platform facilitated 8.1 million euros of loans in August

FELLOW FINANCE PLC PRESS RELEASE 1.9.2020 AT 12:15 PMIn August, Fellow Finance investors funded business and peer-to-peer loans worth of 8.1M€. Cumulative loan volume grew over 648 million euros and the total number of investors grew to 16 516. Check the real-time peer-to-peer lending statistics on our website: www.fellowfinance.com/for-investor/statistics. The performance of business and consumer loans, intermediated by Fellow Finance, can be followed on the company's website: https://www.fellowfinance.com/for-investor/statistics. The return index takes into account payment behaviour

Inzile raises approximately SEK 32.7 million through redemption of series TO 1 warrants

During 1 to 30 August 2020, holders of warrants of series TO 1 of Inzile AB (publ) were able to subscribe for shares through warrants. A total of 2,670,485 shares have been subscribed for, which means a subscription rate of 99.2 percent. Inzile thus raises approximately SEK 32.7 million before issue costs.- We are delighted at the outcome of the redemption of warrants, says Ragnar Åhgren, CEO of Inzile. The proceeds, together with existing cash, will finance the serial production of vehicles during the autumn as well as additional working capital requirements. Inzile issued 5,386,125

Nel ASA: Share capital increase registered

(Oslo, 1 September 2020) Reference is made to the stock exchange announcement on 28 August 2020 regarding the issuance of shares in Nel ASA. The share capital increase pertaining to the issuance of the 6,048,000 new shares has now been registered with the Norwegian Register of Business Enterprises. The Company's new registered share capital is 281,488,697.60, divided into 1,407,443,488 shares, each with a par value of NOK 0.20. ENDS For further information, please contact: Kjell Christian Bjørnsen, CFO, +47 917 02 097 About Nel ASA | www.nelhydrogen.com Nel is a global,

Medicover treats a growing number of Covid-19 patients in India

India has the highest number of daily new confirmed cases of Covid-19 in the world. Medicover is increasing the number of beds in India dedicated for Covid-19 patients, currently 650 beds in 11 hospitals, and the demand for Covid-19 treatment is expected to not only continue but increase through the rest of the year. Elective procedures have reduced but Covid-19 volumes and revenue have more than offset for this shortfall. In total 3,100 Covid-19 patients have been discharged from Medicover’s Indian hospitals since the crisis started. “India is one of the countries in the world that are

Diaverum appoints Krisja Vermeylen to its Board of Directors

Malmö, 1 September 2020: Diaverum, a global leading provider of renal care services, announces the appointment of Krisja Vermeylen to its Board of Directors, and as Chair of the Remuneration Committee.Krisja brings more than 30 years of experience in healthcare and big pharma, the last 20 spent in various management positions at Novo Nordisk and prior to that, several years at Pharmacia (today Pfizer). Ms. Vermeylen is a pharmacist by training and holds a master's degree in pharmaceutical sciences from the University of Antwerp (UIA, RUCA), Belgium. “Krisja Vermeylen is a very

AI and automation power latest release of IFS Customer Engagement, driving improved customer experiences

Highly configurable, integrated and fully branded omnichannel hub lets customers book services and get accurate information online, through social or over the phoneLondon, September 1, 2020 – IFS , the global enterprise applications company, announces the availability of new and enhanced capabilities in its customer engagement software  enabling companies to respond to the challenges facing the traditional call center and transform their customer engagement. IFS is leading the way for service

Composition of Elisa's Shareholders' Nomination Board

ELISA CORPORATION STOCK EXCHANGE RELEASE 1 SEPTEMBER 2020 AT 10:45 AMComposition of Elisa's Shareholders' Nomination Board is following: · Mr Antti Mäkinen, CEO, nominated by Solidium Oy · Mr Jouko Pölönen, President and CEO, nominated by Ilmarinen Mutual Pension Insurance Company · Mr Reima Rytsölä, Deputy CEO, nominated by Varma Mutual Pension Insurance Company · Ms Hanna Hiidenpalo, Director, Chief Investment Officer, nominated by Elo Mutual Pension Insurance Company · Mr Anssi Vanjoki, Chairman of the Board of Elisa  The Nomination Board shall elect the chairman from

Notification of managers’ and closely related parties’ transactions with Dampskibsselskabet NORDEN A/S’ shares in connection with share buy-back program

Announcement no. 32 - 1 September 2020 In connection with the announced share buy-back program in Dampskibsselskabet NORDEN A/S, Motortramp A/S continuously sells shares pro rata and the market is to be informed accordingly – see the attached file. Kind regards, Dampskibsselskabet NORDEN A/S Martin Badsted CFO For further information: Martin Badsted, CFO, tel.: +45 3315 0451Anne-Louise Dam-Rasmussen, Head of Communications, tel.: +45 3273 0624

Fully prepared for the future with new technology and continuous learning

Seppo Lindroos, the founder of Medident Dental Clinic, has seen dentistry evolving quickly over the years. As a technology-enthusiast, he has been eager to develop his competences and learn how to benefit from the latest technology development and incorporate new solutions into his daily workflows. As a latest example, Planmeca’s new intelligent operating lamp with integrated 4K cameras, Planmeca Solanna™ Vision, has quickly become an integrated part of his clinic’s daily work.Seppo Lindroos is an experienced dentist and the founder of Medident dental clinic, located in Helsinki city centre

Riksbank to begin purchasing corporate bonds in September

The Executive Board of the Riksbank has decided to initiate purchases of corporate bonds in the week beginning 14 September 2020. The purchases will keep companies’ funding costs down and reinforce the Riksbank’s capacity to act if the credit supply to companies were to deteriorate further as a result of the corona pandemic.On 30 June 2020, the Executive Board decided that, within its programme for bond purchases, the Riksbank would offer to purchase corporate bonds to a nominal amount of SEK 10 billion between 1 September 2020 and 30 June 2021. The situation on the financial markets has

Change in Optomed’s holding of treasury shares

Optomed Plc         Stock Exchange Release    1 September 2020 at 10.30, Helsinki Change in Optomed’s holding of treasury shares Optomed has conveyed 7,622 treasury shares to the members of the Board of Directors as a part of the Board members' annual remuneration in accordance with the decision of the Annual General Meeting 2020. The amount of shares is based on the monthly remuneration decided by the Annual General Meeting and Optomed's value weighted average share price on 27 August 2020. Furthermore, Mr Jun Wu has informed Optomed that he waives his board remuneration for the

E1/R1 Amateur Photo Award 2019/2020 presents winners

Kompetenzzentrum Wandern WALK announces winner of the Europe-wide photo competition for amateur photographersWith a four-month delay, the Kompetenzzentrum Wandern WALK, Detmold, Germany, announces the winners of this year's E1/R1 Amateur Photo Award. The overall winner, selected from the four category winners, is Stefano Lucchetti with his magnificent photograph "Castelluccio in the Clouds" of the Italian town of Castellucio in the Abruzzo region, which was completely destroyed in an earthquake 2016. The motif was previously selected as the winner of the "Culture and Landscape" category

Strengthened patent protection for arfolitixorin in Japan

GOTHENBURG, Sweden, September 1, 2020 – Isofol Medical AB (publ), (Nasdaq First North Premier Growth Market: ISOFOL), has announced today that the company has further strengthened its position in the second largest market for treatment of mCRC by obtaining two new patent grants for arfolitixorin in Japan. One relates to the preparation process of the drug for injection and one relates to the dosage regimens, including those applied in the ongoing global Phase III study AGENT. Together with the already granted Active Substance Patent (API), these two patents will ensure a strong and extended

All green products start with a Greensource: climate neutrality with Europe’s forest fibre industry

(UPM, Helsinki, 01 September 2020 at 10:00 EET) – UPM is one of the founding members of the #GreenSource initiative, to promote the role of forest-fibre industries in the effort to achieve the EU’s climate neutrality target by 2050. #GreenSource brings together members of EPIS, the European Pulp Industry Sector Association and Cepi, the Confederation of European Paper Industries. The forest fibre industry wish to play a central role in offering solutions that responds to the needs of the European citizens and contribute to a sustainable lifestyle while making sure that forests keep

SpectrumOne acquires the digital marketing agency The Trigger Company AB

Today SpectrumOne acquires the digital marketing agency The Trigger Company AB. The Trigger Company is co-founded by the current CEO. The company is growing and maintaining a positive cashflow.  The purchase price is SEK 6,500,000 and is paid via shares in SpectrumOne AB, with no additional share issue to current shareholders.  In a marketing industry where digitization is becoming the clear path to success The Trigger Company AB has worked with innovative and transparent methods to offer customers fully digitized products. Their aim to make their clients more digitally active is

Adverty announces approval status as the latest vendor to join IAB Europe’s Transparency and Consent Framework

Today, Adverty AB (publ) announced their approved status as the latest vendor to join IAB Europe’s Transparency and Consent framework, designed to help all parties in the digital advertising chain to ensure they comply with data protection regulations (GDPR) and privacy directives.Adverty, the leading in-game platform for advertisers, agencies and content creators, announces their approved status as the latest vendor to join IAB Europe’s Transparency and Consent Framework. The framework, which was launched in April 2018, is designed to help all parties in the digital advertising chain

Management change at Attendo Scandinavia in 2021

Attendo’s current Managing Director for Attendo Scandinavia, Ammy Wehlin, will retire at the turn of the year 2020/2021. In connection with this, Ulrika Eriksson will become the new head of the business area and will join the executive management team.Ammy Wehlin joined Attendo in 2000 as Regional Director, and rapidly advanced to become Managing Director for Attendo Scandinavia. “Ammy has played a prominent role in developing Attendo into the Nordic region’s leading care company, where we have been at the forefront for the past two decades. I want to express my gratitude at this point

Bambuser Partners with Kjell & Company to Offer One-on-One Shopping Experiences to Digital Customers Using Live Streaming Video

Retailer to offer highly-personal e-commerce interactions with experts from across store locations to shoppers directly via mobile, tablet or computer 1 September 2020 | Stockholm – Interactive live video streaming provider Bambuser  and Swedish electronics chain Kjell & Company  today announced a partnership that will enable the retailer to provide customers with live, one-on-one shopping experiences via digital platforms. The initiative expands upon the capabilities of Bambuser’s flagship, pioneering Live Video Shopping technology

Opus has signed an agreement for a proposed sale and leaseback of properties

Opus has signed an agreement for a proposed sale and leaseback of various properties held by Opus. The closing of the sale and leaseback is conditioned upon certain conditions precedent, including buyer’s due diligence. Opus expects to close the transaction in September 2020. The buyer-lessor is Fundamental Income Properties, LLC. The sales price is expected to be approximately SEK 500 million, and the estimated pre-tax gain for Opus Group is around SEK 300 million. The lease agreements will give Opus an initial term and optional renewal terms to allow for a total of up to 35 years. The

Analyses of prevention trials and intralymphatic pilot trial with the diabetes vaccine Diamyd[®] support a positive trend in genetically defined subgroups of type 1 diabetes

A combined analysis of two previous clinical prevention trials, DiAPREV-IT 1 and 2 in healthy children at high risk of type 1 diabetes, as well as additional insights from the open label pilot trial DIAGNODE-1 in children and young adults newly diagnosed with type 1 diabetes, while not reaching statistical significance, are consistent with the recently published large-scale responder analysis which showed a highly significant and clinically relevant effect of the diabetes vaccine Diamyd[®] in individuals positive for for genotypes that include HLA DR3-DQ2.HLA analysis of DiAPREV-IT 1 and 2

Induct - Annonse inntekt per bruker høyere enn prognose for august

Det henvises til kvartalsrapport for Q2 2020, hvor annonseinntektene per bruker var rapportert til å være over kr 10 per aktive bruker. Induct har i august generert en inntekt fra annonser på kr 33,58 per aktive bruker av den nye plattformen. I kalkylene for forretningsmodellen forventet Induct å ligge på ca 1000 annonsevisninger per aktive bruker pr måned, mens antallet visninger i august lå på 945 per aktive bruker. I den samme kalkylen ligger forventet inntekt per 1000 visninger på kr 15 - 20, mens inntekten per 1000 visninger ligger på kr 35,57 i august. «Vi har klart å bevise at

Farxiga demonstrated unprecedented reduction in the risk of kidney failure and cardiovascular or renal death in patients with chronic kidney disease in the Phase III DAPA-CKD trial

1 September 2020 07:00 BST Farxiga demonstrated unprecedented reduction in the risk of kidney failure and cardiovascular or renal death in patients with chronic kidney diseasein the Phase III DAPA-CKD trial Farxiga is the first medicine to significantly prolong survival in a renal outcomes trial in patients with chronic kidney disease with and without type-2 diabetes Detailed results from the ground-breaking Phase III DAPA-CKD trial showed that AstraZeneca's Farxiga (dapagliflozin) on top of standard of care reduced the composite measure of worsening of renal function or risk of

Imfinzi approved in the EU for the treatment of extensive-stage small cell lung cancer

1 September 2020 07:00 BST Imfinzi approved in the EU for the treatment of extensive-stage small cell lung cancer  Only PD-1/PD-L1 immunotherapy to demonstrate a significant survival benefit   and improved response rate in combination with a choice of chemotherapies AstraZeneca's Imfinzi (durvalumab) has been approved in the European Union for the 1st-line treatment of adults with extensive-stage small cell lung cancer (ES-SCLC) in combination with a choice of chemotherapies, etoposide plus either carboplatin or cisplatin. SCLC is a highly aggressive, fast-growing form of

There are no items matching the current filter
There are no more items matching the current filter
Back to top